Valued at a market cap of $8 billion, Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (TECH – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $48.10.

Bio-Techne employs over 3,000 people globally at 34 locations worldwide. As a global developer, manufacturer and supplier of high-quality reagents, analytical instruments and precision diagnostics, ...

Shares of Bio-Techne (NASDAQ:TECH) traded sharply lower in the early premarket trading on Wednesday after KeyBanc Capital Markets downgraded the stock, arguing that the life sciences firm is ...

New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne ...

MINNEAPOLIS, April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association ...

The market expects Techne (TECH) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...

MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest ...